The latest version of eve® can integrate with a wide range of third-party bioreactors and equipment from a number of different suppliers, e.g. Sartorius DCU, Applikon or Matlab. The process data is handled by a single, integrated solution, making the eve® bioprocess platform software a truly universal choice for bioprocess projects.

Bottmingen — eve® offers now a large number of communication protocols, supports all OPC standards and offers a Rest API which can be used to connect analytical devices and softwares. This allows eve® to cover the vast majority of bioreactors, incubator shakers and analytical devices providing the possibility to record bioprocess data from heterogeneous sources into one centralised, common database.

Time-consuming data import/export and format conversion becomes obsolete. Users simply need the eve® user interface, accessible from any computer within a network, to control bioprocesses with a diverse collection of devices within a laboratory.

Combined with the advanced database, comprehensive user management and a detailed audit trail, eve® becomes an universal solution across systems to organise biotech processes from project planning to process control, analysis and acquisition of knowledge.

“Today’s emphasis is on seeing the bioprocess as a whole, rather than having disparate items of hardware and software working semi-independently.”, says Dr. Tony Allman, Product Manager Fermentation at INFORS HT. “We follow this approach by providing eve® as a platform which can cope with all manner of equipment.”

More information about eve® can be found at www.infors-ht.com/eve
INFORS HT wins the Best of Swiss Web Award for eve®

eve®, the bioprocess platform software, was the winner of this year’s Best of Swiss Web award. Thanks to its compelling overall idea, the software solution from INFORS HT is among the bronze winners in the “Business” category.

The Best of Swiss Web Award is an initiative of the simsa (Swiss Internet Industry Association) as well as Netzmedien AG with the aim of promoting transparency and quality standards in the Swiss web and ICT industry. In addition to the many web campaigns and applications represented, eve®, as a web-based platform for the planning, control and analysis of bioprocesses, was unique among the prizewinners.

The decisive factor in awarding eve® the prize was the identifiable added value for the customer, who gains clear competitive advantages thanks to the intelligent integration of workflows, devices, knowledge and big data in one platform.

“One of our target groups is the pharmaceutical industry which creates value from information and knowledge from bioprocess data in order to develop processes for new drugs as quickly as possible,” explains Daniel Egger, member of the executive board and responsible for marketing and software development in the INFORS HT group, who accepted the prize on behalf of the development team. “In this regard, the insights gained from experiments are just as important as the precise control of bioprocesses which are continually optimized based on this knowledge. With the possibility of soft sensors, among others, eve® greatly accelerates easily integrated development processes.”

eve® was developed in close collaboration with the Institute for 4D Technology (i4Ds) of the University of Applied Sciences and Arts Northwestern Switzerland, and thus represents another successful cooperation between Infors AG with a partner from the world of science.

More information about eve® can be found at www.infors-ht.com/eve

More information about the Best of Swiss Web Award: www.bestofswissweb.ch
eve®: The solution for validatable computer-aided systems in GMP processes

Bottmingen 2 May 2017 — For validating its eve® bioprocess bioprocess platform software, INFORS HT now offers validation packages that that support the customer to comply with the requirements of FDA 21 CFR Part 11 and EudraLex Annex 11. Depending on the demand, these packages provide documents such as function specifications, a risk analysis, test protocols and declarations of conformity for FDA and EMA.

Good Manufacturing Practice, or GMP, is a system for ensuring production workflows – one that is mandatory in many areas of the life sciences, pharmacology and biotechnology. As more and more research and production processes incorporate the use of electronic devices, computer-assisted systems and software, the European Medical Agency (EMA) and the US Food & Drug Administration (FDA) have formulated corresponding specifications for computer systems and integrated these into their GMP requirements. These requirements cover technological, administrative and process-related issues, among others, and are spelled out in FDA 21 CFR Part 11 and EudraLex Annex 11.

Thanks to its User Management & Reporting feature, eve®, the bioprocess platform software, offers a customized package intended especially for computer-assisted processes subject to validation requirements. With features such as predefined user roles, audit trails for all planned, ongoing and completed batches, and a comprehensive reporting system with export functionality, ® meets all of the technical requirements for successful validation, making it the ideal solution for legally compliant use within GMP processes.

In addition, INFORS HT also offers two versions of the documentation required for validation. The validation package Basic includes standard documents such as declarations of conformity for the FDA and EMA. The validation package Plus is suitable for projects requiring more detailed documents such as a risk assessment and test protocols.

The requirements of eve® functions with respect to those of FDA 21 CFR Part 11 and EudraLex Annex 11 are assessed in two white papers, which can be downloaded from www-infors-ht.com/eve.
INFORS HT wins iF Gold Award for Minifors 2

Bottmingen / Munich, 22 March 2017 — INFORS HT has been recognised with an award presented by the prestigious iF International Forum. The Minifors 2 bioreactor impressed the jury and was one of only a few companies to receive the iF Gold Award in the discipline “product”.

Each year, Germany’s oldest independent design organization, Hannover-based iF International Forum Design GmbH, bestows the iF DESIGN AWARD. It is one of the most important design prizes in the world and awards design achievements in the following disciplines Product, Packaging, Communication and Service Design, Architecture and Interior Architecture, as well as Professional Concepts. This year only 75 products of 5575 submissions from 59 countries have been chosen for the iF Gold Award.

The compact and easy-to-use bioreactor has impressed the independent 58-member expert jury. The complete package enables both beginners and experienced users to perform a full range of possible applications.

From the jury’s point of view, the user-centred design concept is spot on. “The designers have observed the use of this product in laboratories and refined it as a result of these findings. From a styling point of view, the product communicates quality and trust, from the material choice and finish to a clear user interface design on the large display screen.“. This critique forms the basis of the juries justification for the gold award.

„With Minifors 2 we wanted to set new standards both in design and handling, placing the user in the centre of product development“, says Michael Hawrylenko, CEO of Infors AG. „We are delighted about the iF Gold Award, which honours our concept.“

Minifors 2 has been developed by INFORS HT and designer Stefan Sperling from Meyer-Hayoz Design Engineering. Exceptional thanks goes to Mr. Sperling and the design team for their cooperation during the project.

Learn more about the iF DESIGN AWARD.
Find more information on the Minifors 2 product website.
INFORS HT announces the opening of new US headquarters
February 9, 2017 – INFORS HT, the Swiss manufacturer of bioreactors, shaking incubations and bioprocess software solutions announces the opening of the company’s new US headquarters in Annapolis Junction, Maryland.

The new 27,000 square foot facility houses corporate offices, sales & marketing, service, engineering and all US based manufacturing of incubating shakers and bioreactors.

“The new facility is an important step. This expansion is necessary to keep up with the rapidly growing demand for our cell culture and fermentation products in North America”, says Simon Egli, Director of Sales of INFORS HT.

“These are exciting times. Our business has more than tripled since we went direct in the US three years ago”, says Peter Tunon, CEO of Infors USA Inc. “With our new corporate location, close to three major airports and much of the biotech business on the East coast, and regional offices in California, Massachusetts and Wisconsin, we are well positioned to serve both existing and new customers all over the country”.

An open house is scheduled for February 15. Anyone interested in attending should contact Ms. Crystal Bowens, [email protected] for details.

1234»
TEAM
OUR
PRODUCTS
For more information please visit our Corporate Website:

infors-ht.com